ScreenerHero

EYPTEyePoint, Inc.

NAS · US · Healthcare · Biotechnology · eyepoint.bio
5.320USD-15.56%Mkt Cap: 458.65M $P/E: —

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap458.65M $
Enterprise Value485.06M $
Revenue (TTM)2.79M $
Gross Profit29.30M $
Net Income (TTM)-231.96M $
Revenue/Share0.0340 USD
Last Price5.320 USD
Fiscal Year EndDec 2025
MR QuarterDec 2018
Employees214
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS30233G2093
Valuation
P/E (Trailing)—
P/E (Forward)-1.95
PEG—
EV/EBITDA-1.54
EV/Revenue173.98
P/S162.39
P/B13.64
EPS (TTM)-3.21
EPS (Forward)-2.76
52W Range
3.9509% of range19.11
52W High19.11 USD
52W Low3.950 USD
Profitability
Gross Margin93.41%
Oper. Margin-450.65%
EBITDA Margin0.00%
Profit Margin-739.42%
ROE-75.78%
ROA-63.73%
Growth
Revenue Growth161.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-240.11M $
CapEx (TTM)3.28M $
FCF Margin-5559.92%
FCF Yield-33.80%
Net Debt-27.64M $
Net Debt/EBITDA0.09
Balance Sheet
Debt/Equity0.07
Current Ratio4.50
Quick Ratio4.30
Book Value/Sh0.3960 USD
Cash/Share0.4770 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateDec 9, 2020
Splits
Last Split1:10
Split DateDec 9, 2020
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)27.36 USD
Upside (mean)+414.4%
Target Range5.000 USD – 68.00 USD
$5.000+414.4% to mean$68.00
# Analysts11
Ownership
Shares Out.86.21M
Float66.83M
Insiders3.60%
Institutions111.20%
Short Interest
Short Ratio11.4d
Short % Float21.99%
Short % Out.20.90%
Shares Short18.02M
Short (prev mo.)15.11M
Technical
SMA 5012.65 (-58.0%)
SMA 20014.02 (-62.0%)
Beta1.74
S&P 52W Chg18.16%
Avg Vol (30d)3.77M
Avg Vol (10d)9.61M
Technical Indicators
RSI (14)29.6
MACD-1.3380
MACD Signal-0.5305
MACD Hist.-0.8076
BB Upper17.22 USD
BB Middle11.67 USD
BB Lower6.130 USD
BB Width94.98%
ATR (14)1.599 USD
Vol Ratio (20d)1.77x